CRSP CRISPR Therapeutics AG

CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry

CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
EN
07/10/2020

Underlying

CRSPCRISPR Therapeutics AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CRISPR Therapeutics AG

 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics Named to TIME’s Most Influential Companies List of...

CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025 ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, has been named to the fifth annual  list. The Company was recognized in the Pioneers category for its groundbreaking work in advancing the field of gene editing.  TIME highlighted CRISPR Therapeutics’ expansion beyond its landmark success in treating sickle cell disease and beta thalassemia, noting the Company’s...

June 30, 2025 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX31...

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline -New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025- -Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026- -Pre...

June 26, 2025 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics to Participate in Upcoming Investor Conferences ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. William Blair’s 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 11:20 a.m. CT Goldman Sachs’ 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 3...

May 29, 2025 1 EN
Research Team ACF
  • Research Team ACF
DXCM DEXCOM INC.
VRTX Vertex Pharmace... ... (+19)

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

DXCM DEXCOM INC.
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
05/29/25 May 29, 2025 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Coll...

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies -Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small interfering RNA (siRNA) for the treatment of thromboembolic disorders- -SRSD107 demonstrated peak reductions in FXI activity >93% and increases in activated partial thromboplastin time (aPTT) >2x with maintained efficacy up to 6 months post-dosing in a Phase 1 clinical trial- -Under the agreement, CRISPR Therapeutics will mak...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch